Journal
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY
Volume 17, Issue 9, Pages 1574-1578Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.sapharm.2020.12.003
Keywords
Community pharmacy; Point-of-care testing; CLIA-Waived laboratories; COVID-19
Ask authors/readers for more resources
The study updated the national benching report and examined the number of pharmacies with CLIA Certificates of Waiver in the United States before and after the SARS-CoV-2 pandemic, as well as the state-by-state differences in the percentage of pharmacies with CLIA Certificates of Waiver. Pharmacies showed significant growth in becoming an important location for accessing CLIA-waived tests, especially between 2019 and 2020 due to the COVID-19 pandemic.
Background: The Clinical Laboratory Improvement Amendments of 1988 (CLIA) enabled greater access to lowrisk tests by allowing their use in facilities with a Certificate of Waiver in the U.S. Recently, the 2019 novel coronavirus (COVID-19) pandemic has shined a spotlight on CLIA-waived diagnostic testing. To meet this increased patient demand for diagnostic testing, the U.S. Department of Health and Human Services (HHS) authorized licensed pharmacists to order and administer FDA authorized COVID-19 tests. Objective: This study aims to update the previous national benching report and examine both the number of pharmacies in the United States with CLIA Certificates of Waiver before and after the SARS-CoV-2 pandemic and the state-by-state differences in the percentage of pharmacies with CLIA Certificates of Waiver. Methods: Data were collected from the U.S. Centers for Disease Control and Prevention CLIA Laboratory Search website May 3rd, 2015, August 4th, 2019 and November 26th, 2020. The website allows for exportation of demographic data on all CLIA-waived facilities by state. Results: Pharmacies exhibited the largest growth both in number (4865 new locations) and by percent (45%) of CLIA-waived facilities between 2015 and 2020. The total number of pharmacies with a CLIA-waiver grew from 10,626 (17.94%) locations in 2015 to 12,157 (21.43%) locations in 2019, to 15,671 (27.63%) locations in 2020. States demonstrated considerable variability in the percentage of pharmacies with a CLIA-waiver, with a range of 2.92%-56.52%. Conclusions: Pharmacies have become an increasingly important location for patients to access CLIA-waived tests in the United States, now serving as the second largest provider of CLIA-waived tests by the total number of locations. Most of this growth occurred between 2019 and 2020 due to the COVID-19 pandemic, and concentrated efforts will be necessary to sustain this momentum.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available